Cyclerion Therapeutics, Inc. (NASDAQ:KRSA) Stock Has Average Price Target of $53.00

Cyclerion Therapeutics, Inc. (NASDAQ:KRSA) has been assigned a consensus recommendation of “Moderate Buy” from the seven ratings firms that are currently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, four have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $53.00.

Several analysts recently commented on the stock. UBS Group assumed coverage on shares of Cyclerion Therapeutics in a research note on Friday, September 11th. They set a “buy” rating and a $55.00 target price for the company. Zacks Research upgraded shares of Cyclerion Therapeutics to a “hold” rating in a research report on Wednesday, September 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cyclerion Therapeutics in a report on Friday, July 24th. Stifel Nicolaus started coverage on Cyclerion Therapeutics in a report on Monday, September 14th. They issued a “buy” rating and a $43.00 price target on the stock. Finally, TD Cowen started coverage on Cyclerion Therapeutics in a research report on Monday, September 14th. They set a “buy” rating for the company.

Cyclerion Therapeutics Trading Down 0.3%

NASDAQ:KRSA opened at $30.14 on Wednesday. Cyclerion Therapeutics has a twelve month low of $7.19 and a twelve month high of $59.36.

Institutional Investors Weigh In On Cyclerion Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Braidwell LP purchased a new stake in shares of Cyclerion Therapeutics during the second quarter valued at $532,000. ADAR1 Capital Management LLC purchased a new position in Cyclerion Therapeutics in the 2nd quarter worth about $1,013,000. Finally, BlackRock Inc. purchased a new position in Cyclerion Therapeutics in the 2nd quarter worth about $57,000. 75.62% of the stock is owned by institutional investors and hedge funds.

Cyclerion Therapeutics Company Profile

Cyclerion Therapeutics, Inc was a clinical-stage biopharmaceutical company focused on developing medicines for serious central nervous system and cardiopulmonary diseases. The company’s research centered on soluble guanylate cyclase (sGC) stimulators, a class of compounds intended to regulate cellular signaling and potentially address diseases associated with impaired nitric oxide signaling.

Cyclerion was formed in 2019 as a spin-off from Ironwood Pharmaceuticals. Its historical development portfolio included olinciguat, an investigational treatment studied for sickle cell disease, and praliciguat, which was evaluated for conditions including diabetic nephropathy and nonalcoholic steatohepatitis.